Share information
200.90 €
-1.66 %
05/10/2026 17:37
-1.66 %
Open
High
Low
Volume
205.00 €
205.30 €
200.90 €
159,633
Latest News
30-Sep-2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa
29-Sep-2026
UCB data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG
09-Sep-2026
UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA[®] (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
08-Sep-2026
UCB opens ‘Expressing Epilepsy’ art exhibition featuring acclaimed artists living with epilepsy